Response to correspondence concerning: “Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients”

Lammers, A J Jolanda; Brohet, Richard M.; Theunissen, R. E.P.; Köster, Corinna; Rood, Richard P.; Verhagen, Dominique W M; Brinkman, Kees; Hassing, Robert Jan; Dofferhoff, Anton S M; Moussaoui, R. El; Hermanides, Gonneke; Ellerbroek, Jacobien; Bokhizzou, Nejma; Visser, Hannah; Berge, Marcel van den; Bax, Hannelore I.; Postma, Douwe F.; Groeneveld, P. H. P.

doi:10.1016/j.ijid.2020.12.008

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the beginning of 2020, decades of publications were released either favoring or discouraging the use of Azi, both with or without HQL [ 70 ]. According to them, Azi was initially favored with or without HQL [ 72 , 73 , 74 , 75 , 76 , 77 ] but at the same time more observations did not favor its use [ 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 ]. Since most of them were retrospective studies, it was clear that randomized control trials (RCTs) were necessary to clarify the previous controversial data.…”

Section: Azithromycin and Betacoronovirusmentioning

confidence: 99%

Azithromycin through the Lens of the COVID-19 Treatment

Kournoutou

Dinos

2022

Antibiotics

View full text Add to dashboard Cite

Azithromycin has become famous in the last two years, not for its main antimicrobial effect, but for its potential use as a therapeutic agent for COVID-19 infection. Initially, there were some promising results that supported its use, but it has become clear that scientific results are insufficient to support such a positive assessment. In this review we will present all the literature data concerning the activity of azithromycin as an antimicrobial, an anti-inflammatory, or an antivirus agent. Our aim is to conclude whether its selection should remain as a valuable antivirus agent or if its use simply has an indirect therapeutic contribution due to its antimicrobial and/or immunomodulatory activity, and therefore, if its further use for COVID-19 treatment should be interrupted. This halt will prevent further antibiotic resistance expansion and will keep azithromycin as a valuable anti-infective therapeutic agent.

show abstract

Section: Azithromycin and Betacoronovirusmentioning

confidence: 99%

Azithromycin through the Lens of the COVID-19 Treatment

Kournoutou

Dinos

2022

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Further observational studies evaluating the efficacy and safety of HCQ and CQ use were conducted in multiple regions of the world. [44][45][46][47][48] In one retrospective cohort study in the New York metropolitan area, a total of 1,438 patients with confirmed COVID-19 were included. 44 Patients were placed into 1 of 4 treatment groups: HCQ, azithromycin, azithromycin with HCQ, or neither drug.…”

Section: Large Observational Datamentioning

confidence: 99%

“…In The Netherlands, investigators also conducted a retrospective cohort study to compare patient outcomes when treated with HCQ, CQ, or neither drug. 47 A total of 1,064 eligible patients were included. Of those, 189 received HCQ, 377 received CQ, and 498 patients didn't receive treatment.…”

Section: Large Observational Datamentioning

confidence: 99%

The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19

Aljadeed

2021

Journal of Pharmacy Practice

View full text Add to dashboard Cite

On March 11th, the World Health Organization (WHO) announced the unprecedented outbreak of “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) to be a pandemic. Thus far, COVID-19 has infected over 58,229,138 individuals and caused 1,382,106 deaths worldwide. This has led to the re-purposing of available drugs under “off-label” use—drugs such as hydroxychloroquine and chloroquine. Both drugs have since been evaluated for their ability to treat COVID-19. Here, we summarize recent evidence regarding the use of hydroxychloroquine and chloroquine in hospitalized patients with COVID-19. All data is current as of November 23, 2020.

show abstract

Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules

Oktavianawati,

Santoso,

Bakar

et al. 2023

Appl Biol Chem

View full text Add to dashboard Cite

COVID-19 has been a major global health concern for the past three years, and currently we are still experiencing coronavirus patients in the following years. The virus, known as SARS-CoV-2, shares a similar genomic identity with previous viruses such as SARS-CoV and MERS-CoV. To combat the pandemic, modern drugs discovery techniques such as in silico experiments for docking and virtual screening have been employed to design new drugs against COVID-19. However, the release of new drugs for human use requires two safety assessment steps consisting of preclinical and clinical trials. To bypass these steps, scientists are exploring the potential of repurposing existing drugs for COVID-19 treatment. This approach involves evaluating antiviral activity of drugs previously used for treating respiratory diseases against other enveloped viruses such as HPV, HSV, and HIV. The aim of this study is to review repurposing of existing drugs, traditional medicines, and active secondary metabolites from plant-based natural products that target specific protein enzymes related to SARS-CoV-2. The review also analyzes the chemical structure and activity relationship between selected active molecules, particularly flavonol groups, as ligands and proteins or active sites of SARS-CoV-2.

show abstract

Response to correspondence concerning: “Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients”

Cited by 3 publications

References 0 publications

Azithromycin through the Lens of the COVID-19 Treatment

Azithromycin through the Lens of the COVID-19 Treatment

The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19

Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules

Contact Info

Product

Resources

About